Abstract
Objectives To evaluate the impact of a 91-day extended regimen combined oral contraceptive (150 μg levonorgestrel [LNG]/30 μg ethinylestradiol [EE] for 84 days, followed by 10 μg EE for seven days [Treatment 1]) compared with two traditional 21/7 regimens (21 days 150 μg LNG/30 μg EE [Treatment 2] or 150 μg desogestrel [DSG]/30 μg EE [Treatment 3], both with seven days’ hormone free), on several coagulation factors and thrombin formation markers.Methods Randomised, open-label, parallel-group comparative study involving healthy women (18–40 years). The primary endpoint was change from baseline in prothrombin fragment 1 + 2 (F1 + 2) levels over six months.Results A total of 187 subjects were included in the primary analysis. In all groups, mean F1 + 2 values were elevated after six months of treatment. Changes were comparable between Treatments 1 and 2 (least squares mean change: 170 pmol/L and 158 pmol/L, respectively) but noticeably larger after Treatment 3 (least squares mean change: 592 pmol/L). The haemostatic effects of Treatment 1 were comparable to those of Treatment 2 and noninferior to those of Treatment 3 (lower limit of 95% confidence interval [− 18.3 pmol/L] > − 130 pmol/L).Conclusions The LNG/EE regimens had similar effects on F1 + 2. Noninferiority was demonstrated between extended regimen LNG/EE and DSG/EE.Chinese 摘 要 目的 评估口服避孕药91天长周期疗法(150μg左炔诺孕酮[levonorgestrel,LNG]/30μg炔雌醇[ethinylestradiol,EE]84天,10μg EE 7天[治疗1])与两种21/7常规方案(21天150μg LNG/30μg EE [治疗2]或150μg去氧孕烯[desogestrel,DSG]/30μg EE [治疗3],两种治疗均有7天的间歇期)对凝血因子和凝血酶形成标记物的影响。方法 关于18-40岁健康女性的随机、开放、平行组对照研究。主要研究终点为治疗6个月后凝血酶原片段F1+2与基线水平的变化。结果 初步分析了187名受试者,治疗6个月后整个人群的F1+2平均水平上升。治疗1与治疗2的变化类似:最小二乘均数变化分别为170 pmol/L和158 pmol/L,但治疗3的变化明显大:最小二乘均数变化为592 pmol/L。治疗1的止血效果与治疗2的相似,但不比治疗3差(95%置信区间下限[ -18.3 pmol/L] > -130 pmol/L)。结论 LNG/EE两种治疗方案对F1+2的影响相似,LNG/EE长周期方案与DSG/EE常规方案相比无差别。
Highlights
COCs are known to affect certain haemostatic indices[2,18]; it is unclear the extent to which these changes reflect the risk of venous thromboembolism (VTE) associated with COCs
Guidance provided in 2001 by the Committee for Property Medicinal Products of the European Medicines Agency (EMA) advised that there was no urgency to modify the pattern of COC prescriptions, those containing LNG should be preferred over third-generation regimens for first time users[19]
A recent review by the EMA’s Committee for Medicinal Products for Human Use concluded that the absolute risk forVTE with low-dose combined hormonal contraceptives is small and the risk associated with these agents is lowest for regimens containing LNG, norethisterone, or norgestimate[20]
Summary
To evaluate the impact of a 91-day extended regimen combined oral contraceptive (150 μg levonorgestrel [LNG]/30 μg ethinylestradiol [EE] for 84 days, followed by 10 μg EE for seven days [Treatment 1]) compared with two traditional 21/7 regimens (21 days 150 μg LNG/30 μg EE [Treatment 2] or 150 μg desogestrel [DSG]/30 μg EE [Treatment 3], both with seven days’ hormone free), on several coagulation factors and thrombin formation markers. Methods Randomised, open-label, parallel-group comparative study involving healthy women (18–40 years).The primary endpoint was change from baseline in prothrombin fragment 1 ϩ 2 (F1 ϩ 2) levels over six months. Results A total of 187 subjects were included in the primary analysis. Mean F1 ϩ 2 values were elevated after six months of treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: The European Journal of Contraception & Reproductive Health Care
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.